ArticleVeterinary world2015
Comparative study on the immunopotentiator effect of ISA 201, ISA 61, ISA 50, ISA 206 used in trivalent foot and mouth disease vaccine.
Article in Veterinary world, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 69 citations in OpenAlex.
- Evaluation of an Effective Intradermal Foot-and-Mouth Disease Vaccine for Early Protection.Vaccines · 2026Article
- A novel killed oil adjuvanted bovine viral diarrhea virus vaccine protects from viremia and clinical manifestations: an immune response and challenge study in cattle.Veterinary research communications · 2025Article
- Fourteen anti-tick vaccine targets are variably conserved in cattle fever ticks.Parasites & vectors · 2025Article
- Comparative evaluation of protective efficacy of experimental inactivated vaccines against haemorrhagic septicaemia.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Astragalus Polysaccharide Nanoemulsion: A Promising Adjuvant for Foot-And-Mouth Disease Virus-Like Particle Vaccines.Transboundary and emerging diseases · 2025Article
- Enhanced Immunogenicity of Foot-and-Mouth Disease Virus-like Particles Using a Water-in-Oil-in-Water Adjuvant.Vaccines · 2024Article
- Development and Evaluation of a Candidate Inactivated Vaccine Against Bluetongue Virus Serotype 4 (BTV4).Vaccines · 2024Article
- Enhanced Effects of ISA 207 Adjuvant via Intradermal Route in Foot-and-Mouth Disease Vaccine for Pigs.Vaccines · 2024Article
- Immunization of cattle with aParasitology · 2024Article
- Immunogenicity of an InactivatedVaccines · 2024Article
- Comparative study on alginate/chitosan microcapsules and Montanide ISA 61 as vaccine adjuvants in mice.PloS one · 2024Article
- Isoprinosine as a foot-and-mouth disease vaccine adjuvant elicits robust host defense against viral infection through immunomodulation.Frontiers in cellular and infection microbiology · 2024Article
- Compared to Aluminum Hydroxide Adjuvant, Montanide ISA 206 VG Induces a Higher and More Durable Neutralizing Antibody Response against FMDV in Goats.Archives of Razi Institute · 2023Article
- An Oil-Based Adjuvant Improves Immune Responses Induced by Canine Adenovirus-Vectored Vaccine in Mice.Viruses · 2023Article
- Combined Adjuvant Formulations Enhanced an Immune Response of Trivalent Foot and Mouth Disease Vaccine in Cattle.Veterinary medicine (Auckland, N.Z.) · 2023Article
- Efficacy of a Novel Multiepitope Vaccine Candidate against Foot-and-Mouth Disease Virus Serotype O and A.Vaccines · 2022Article
- Improved safety profile of inactivated Neethling strain of the Lumpy Skin Disease Vaccine.Vaccine: X · 2022Article
- Safety and Efficacy of thePharmaceutics · 2022Article
- Recombinant AhpC antigen fromTurkish journal of biology = Turk biyoloji dergisi · 2022Article
- Screening immune adjuvants for an inactivated vaccine againstFrontiers in veterinary science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimA comparison study was conducted to explore the best internationally available adjuvant that could be used in production of a highly potent foot and mouth disease (FMD) vaccine, that could stimulate a strong immune response and possibly give greater protection against FMD. MATERIALS AND
methodsFour experimental batches of trivalent FMD vaccine were prepared with different available oil adjuvants which included Montanide ISA 201, 206, 61 and 50.
resultsThe results indicated that vaccines emulsified using Montanide ISA 201 and Montanide ISA 206 adjuvants elicited a protective humoral immune response from the 2(nd) week postvaccination (WPV) as for ISA 201 with serum neutralization test (SNT) and enzyme-linked immune sorbent assay (ELISA) antibody titers of 1.62±0.047(a) and 1.8±0.049(a), 1.59±0.076(a) and 1.836±0.077(a), and 1.71±0.06(b) and 1.96±0.074(b) for serotypes O, A, SAT2, respectively, and for ISA 206 at SNT and ELISA antibody titers of 1.5±0.082(a) and 1.84±0.084(a), 1.56±0.037(a) and 1.818±0.052(a), and 1.5±0.106(a,b) and 1.81±0.104(a,b) for FMD virus serotypes O, A and SAT2, respectively. For ISA 61 and ISA 50, the protective antibody titer appeared in the 3(rd) WPV. In the ISA 61 FMD vaccine, SNT and ELISA titer were 1.59±0.076(a) and 1.9±0.094(a), 1.53±0.056(a) and 1.83±0.070(a), and 1.5±0.082(a) and 1.84±0.094(a) for serotypes O, A and SAT2, respectively, and in the case of ISA 50 FMD vaccine, the SNT, and ELISA titer were recorded for serotypes O, A and SAT2 respectively, 1.59±0.037(a) and 1.8±0.030(a), 1.68±0.056(a,b) and 1.916±0.065(a,b), and 1.65±0.082(a) and 1.9±0.09(a). On estimating the cellular immune response, the highest delta optical density levels for ISA 201 (0.395-0.460) and ISA 206 (0.375-0.428) were observed on 14 and 21 days post vaccination (DPV) respectively, while the highest levels of lymphoproliferation for ISA 61 (0.375-0.455) and ISA 50 (0.411-0.430) were on 21 and 28 DPV, respectively.
conclusionThe duration of immunity from Montanide ISA oils (201, 206, 61 and 50) FMD vaccines is a long-lived immunity which ranged between 32 and 38 weeks post vaccination but the Montanide ISA 201 FMD vaccine is superior to the others in the rapid cellular immune response of the vaccinated animals which showed its highest level within 14 days post vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.